Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT ID: NCT03128411 Phase: PHASE2 Status: COMPLETED Enrollment: 64 Completion: 2021-03-04
Conditions
Leukemia, Chronic Myelogenous
Interventions
Bosutinib
Summary
Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.
Primary Outcome
Percentage of Participants With Major Molecular Response (MMR) at Month 12